Sionna's Trikafta-Confounded Phase 2a Failure Forces High-Stakes Dual Combination Bet With Depleted Resources

Sionna Advances SION-451 + SION-2222 Dual Combination to Phase 2a

Sionna Therapeutics plans to advance its SION-451 + SION-2222 dual combination into the AscenSION CF Phase 2a proof-of-concept trial. This decision follows a comprehensive post hoc analysis of the PreciSION CF Phase 2a trial for SION-719, which did not meet its primary endpoint. The analysis suggested that SION-719 was biologically active but its effect was confounded by PK outliers and complex interactions with Trikafta. The company also announced a 46% workforce reduction and other cost-saving measures to extend its cash runway into the second half of 2029, prioritizing the dual combination program.

• Sionna Therapeutics is moving its SION-451 + SION-2222 dual combination into the AscenSION CF Phase 2a proof-of-concept trial, expected to start in Q1 2027. This decision is based on favorable Phase 1 results for the combination and insights from a post hoc analysis of the PreciSION CF trial, reinforcing the belief in the NBD1 stabilization approach for cystic fibrosis.
• A detailed post hoc analysis of the SION-719 PreciSION CF Phase 2a trial, which initially failed its key activity endpoint, revealed confounding factors. These included PK outliers and lower Trikafta exposures during SION-719 treatment, as well as potential blunting interactions between SION-719 and ivacaftor. Excluding confounded participants, a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L was observed, suggesting SION-719's biological activity.
• Sionna has implemented a significant corporate restructuring, including a 46% workforce reduction and other cost-saving measures. These actions are designed to focus resources on the SION-451 + SION-2222 dual combination program and are expected to extend the company's cash runway into the second half of 2029, from an ending Q2 2026 cash position of $268.3 million.

Unpacking PreciSION CF: Learnings for NBD1 Stabilization in CF

Three recent clinical studies in cystic fibrosis (CF) offer meaningful efficacy and safety data across distinct patient populations and therapeutic interventions.

The phase 3 trial VX17-445-102 evaluated elexacaftor-tezacaftor-ivacaftor in patients 12 years of age or older with Phe508del-minimal function genotypes over 24 weeks. Relative to placebo, the triple combination produced a 13.8 percentage-point improvement in percentage of predicted forced expiratory volume in 1 second (FEV1) at week 4 and 14.3 percentage points through 24 weeks, a 63% lower rate of pulmonary exacerbations, a 20.2-point improvement in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score, and a 41.8 mmol per liter reduction in sweat chloride concentration (P<0.001 for all comparisons). The regimen was "generally safe and had an acceptable side-effect profile," with most adverse events rated mild or moderate and discontinuation due to adverse events occurring in 1% of the elexacaftor-tezacaftor-ivacaftor group.

The phase 3 trial 445-124 assessed elexacaftor/tezacaftor/ivacaftor in participants carrying 1 of 18 rare CFTR variants with no F508del allele over 24 weeks. Mean improvements were observed in the primary endpoint of percent predicted FEV1 (9.2 percentage points; 95% CI: 7.2, 11.3; P<0.0001), sweat chloride (-28.3 mmol/L; 95% CI: -32.1, -24.5 mmol/L; P<0.0001), and CFQ-R respiratory domain score (19.5 points; 95% CI: 15.5, 23.5; P<0.0001). A complementary network meta-analysis of CFTR modulators — incorporating data from 13 randomized studies — ranked vanzacaftor-tezacaftor-deutivacaftor first and elexacaftor-tezacaftor-ivacaftor second by P-score, with both demonstrating effects on ppFEV1 and CFQ-R scores "almost quadruple" those of tezacaftor-ivacaftor and lumacaftor-ivacaftor versus placebo. A statistically significant difference between vanzacaftor-tezacaftor-deutivacaftor and elexacaftor-tezacaftor-ivacaftor was noted specifically in sweat chloride reduction (mean difference: -8.59; 95% CI: -15.53, -1.65).

AscenSION CF: Designing the Next Phase for SION-451 + SION-2222

Several key cystic fibrosis (CF) clinical trials have employed rigorous, controlled designs to evaluate CFTR modulator therapies across distinct genotypic populations and age groups. The trials span Phase 2 and Phase 3 development, with endpoints anchored in both functional and structural measures of disease.

• RECOVER Trial (NCT04602468): A real-world, multi-site study conducted across seven sites in Ireland and the United Kingdom, enrolling 117 participants aged 12 years and older who were either homozygous for F508del (F508del/F508del) or heterozygous for F508del and a minimum-function mutation (F508del/MF). Participants were recruited prior to initiating elexacaftor/tezacaftor/ivacaftor (ETI) and followed over 12 months. Primary endpoints were lung clearance index (LCI) and FEV1. Secondary endpoints included spirometry-controlled chest computed tomography (CT) scores assessed using the Perth Rotterdam Annotated Grid Morphometric Analysis (PRAGMA) system, with CT scans performed at baseline and 12 months. Additional outcome measures included weight, height, Cystic Fibrosis Quality of Life Questionnaire-Revised (CFQ-R), and sweat chloride.

• TEZ/IVA in F/Gating Genotypes — Phase 3 (NCT02412111): A randomized, double-blind, ivacaftor-controlled, parallel-group study in participants aged 12 years and older heterozygous for F508del-CFTR and a gating mutation. Enrolled participants entered a 4-week ivacaftor run-in period to establish a stable baseline, followed by 8 weeks of randomized treatment with either ivacaftor or tezacaftor/ivacaftor. The primary endpoint was absolute change in percent predicted FEV1 (ppFEV1). Key secondary endpoints were relative change in ppFEV1 and absolute change in CF Questionnaire-Revised respiratory domain score. Additional secondary endpoints included absolute change in sweat chloride (SwCl) concentration, pharmacokinetic parameters, and safety.

• TEZ/IVA in Participants Aged 6–11 Years — Phase 3: A randomized (4:1), double-blind study evaluating tezacaftor/ivacaftor over 8 weeks in participants aged 6 through 11 years with F/F or F/RF genotypes. The primary endpoint was within-group change from baseline in the lung clearance index 2.5 (LCI2.5) through Week 8. Secondary endpoints were change from baseline in sweat chloride (SwCl), CFQ-R respiratory domain score, and safety.

• ETI in CFTR N1303K — Prospective Open-Label Trial (NCT03506061): A prospective, multicentre, open-label, single-arm trial at two CF centres in the USA, enrolling participants aged 12 years or older with at least one N1303K variant and at least one CFTR allele who were ineligible for modulator therapy per FDA labelling. Participants received ETI for 28 days followed by a 28-day washout period. The primary endpoint was mean change in sweat chloride from baseline up to day 28. Secondary endpoints were changes in ppFEV1, CFQ-R respiratory domain score, BMI, and weight after ETI therapy.

• Vanzacaftor-Tezacaftor-Deutivacaftor — Phase 2 Trials (NCT03911713 and NCT03912233): Two phase 2 randomized, double-blind, controlled studies in adults aged 18 years or older. Study VX18-561-101 compared deutivacaftor monotherapy with ivacaftor monotherapy in participants with CFTR gating mutations following a 4-week ivacaftor run-in; the primary endpoint was absolute change in ppFEV1 from baseline at week 12. Study VX18-121-101 evaluated vanzacaftor-tezacaftor-deutivacaftor in participants with F/MF or F/F genotypes over 4 weeks; primary endpoints for its two parts were safety and tolerability and absolute change in ppFEV1 from baseline to day 29. Secondary efficacy endpoints in VX18-121-101 were absolute change from baseline at day 29 in sweat chloride concentrations and CFQ-R respiratory domain score.

• LFT Safety Study Across Three CF Trials: A cohort study comprising participants from three completed multicenter CF trials, with an average follow-up of 8.3 months. Liver function tests (LFTs) were collected as safety endpoints; hospitalization rates and changes in pulmonary function and weight were used to assess the association between elevated LFTs and clinical outcomes.

Addressing Unmet Needs in CF with NBD1 Stabilization

Despite remarkable advances in CFTR modulator therapy, a meaningful subset of people with cystic fibrosis remains without adequate treatment options. Research over the past three years has concentrated on several distinct populations and molecular challenges that current standard-of-care therapies do not adequately address.

• Patients carrying nonsense (premature termination codon) mutations: Approximately 9% of CF mutations are premature termination codons (PTCs), which typically cause severe CFTR expression defects and render patients unresponsive to existing CFTR modulators. Nonsense suppression (readthrough) therapy — using small molecules such as G418, NV848, NV914, and NV930 — is being actively investigated to rescue full-length, functional CFTR protein in this population. Studies have further shown that combining translational readthrough-inducing molecules with Elexacaftor-Tezacaftor-Ivacaftor and the nonsense-mediated mRNA decay inhibitor NMDI14 can enhance CFTR activity in patient-derived intestinal organoids carrying the W1282X variant.

• The estimated 10–15% of the global CF population ineligible for or intolerant to current CFTR-targeting therapies: This group, which includes patients with rare or genetically ineligible variants, is the primary target for gene-based approaches. Lentiviral gene addition therapy — specifically a third-generation lentiviral vector pseudotyped with Sendai virus F and HN envelope proteins (rSIV.F/HN) carrying a full-length CFTR transgene (BI 3720931) — has advanced to a first-in-human clinical trial. CRISPR-Cas9-based gene editing strategies are also being explored, with F508del and W1282X as the most extensively studied targets, alongside over fifteen other CF-causing variants.

• Infants and young children, including those with prenatal ETI exposure: There is a recognized lack of robust, real-world longitudinal data on CFTR modulator therapy in infants and young children, where extrapulmonary outcomes such as growth, micronutrient status, and pancreatic function are the key focus. Case reports have further identified that while prenatal Elexacaftor/Tezacaftor/Ivacaftor (ETI) exposure can preserve pancreatic function, ongoing postnatal ETI exposure may be necessary to prevent pancreatic damage — suggesting a role for early ETI therapy in prenatally exposed infants.

• Patients with rare CFTR variants lacking approved therapies: Approximately 18% of people with cystic fibrosis carry rare CFTR variants, including nonsense variants, and often lack access to highly effective modulator treatments such as the Elexacaftor-Tezacaftor-Ivacaftor combination. Research efforts are focused on understanding the effects of these variants on disease severity and response to treatment, with patient-derived intestinal organoids being leveraged to evaluate mutation-specific therapeutic responses and support the development of personalized therapies.

• CF patients with Mycobacterium abscessus pulmonary co-infection: People with CF face a significant risk for pulmonary infections with non-tuberculous mycobacteria, particularly Mycobacterium abscessus (Mab), which causes progressive pulmonary dysfunction and increased morbidity and mortality. Despite advances in CF care including CFTR modulators, Mab continues to pose a therapeutic challenge, with significant long-term medical burden, and no vaccine is currently available in clinical development for this pathogen.

Sionna's Strategic Pivot: A Dual Combination Bet in CF

The landscape for cystic fibrosis (CF) treatment has been profoundly reshaped by the advent of CFTR modulators, particularly multi-drug regimens like Trikafta. These combinations, comprising correctors and potentiators, have demonstrated remarkable efficacy in restoring the function of the F508del-CFTR protein, which is responsible for the most common CF mutation. The scientific understanding is clear: synergistic action from multiple modulators is key to achieving significant clinical benefits.

Sionna Therapeutics' recent announcement reflects a strategic recalibration in this challenging environment. The company's decision to pivot from its single-agent SION-719, which showed biological activity but was hampered by pharmacokinetic (PK) outliers and complex interactions with existing therapies, to a dual combination of SION-451 + SION-2222, is a direct response to this established paradigm. This move suggests an intent to leverage the synergistic potential of multiple agents, a strategy supported by research indicating the value of integrated screening for effective corrector and potentiator combinations.

However, this strategic shift comes with inherent risks. The bar for efficacy is exceptionally high, set by the profound clinical benefits of current triple combinations. Any new therapy must demonstrate a compelling advantage, whether in superior efficacy, improved tolerability, or applicability to specific patient populations. Furthermore, the previous challenges with SION-719's PK and drug-drug interactions (DDIs) are a critical consideration. Existing CFTR modulators are known to have complex metabolism, often involving CYP3A, leading to significant DDIs with other medications. The new dual combination will need to navigate these complexities to ensure a predictable and safe profile. The company's significant workforce reduction and cost-saving measures, while extending its financial runway, underscore the intense pressure on this dual combination program to deliver robust, differentiated clinical data. The success of SION-451 + SION-2222 in its upcoming Phase 2a trial will be pivotal in determining Sionna's future trajectory in the competitive CF therapeutic space.